Immunotherapy in Epidermal Growth Factor Receptor-mutant Non-small Cell Lung Cancer
Targeted therapy and immunotherapy are important treatments for non-small cell lung cancer (NSCLC). At present, the clinical and basic research of epidermal growth factor receptor (EGFR) mutation NSCLC is still in the exploratory stage, needing to optimize the efficacy, combination, sequence and dos...
Main Authors: | Xin WANG, Diansheng ZHONG |
---|---|
Format: | Article |
Language: | zho |
Published: |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association
2019-08-01
|
Series: | Chinese Journal of Lung Cancer |
Subjects: | |
Online Access: | http://dx.doi.org/10.3779/j.issn.1009-3419.2019.08.11 |
Similar Items
-
Molecular Mechanism of Erlotinib Resistance in Epidermal Growth Factor Receptor
Mutant Non-small cell Lung Cancer Cell Line H1650
by: Ruili HAN, et al.
Published: (2012-12-01) -
Analysis of the Efficacy of Immunotherapy on the Posterior Lines
of Advanced EGFR Mutant Patients with Non-small cell Lung Cancer
by: Li MA, et al.
Published: (2021-05-01) -
Epidermal Growth Factor Receptor Mutations and Radiotherapy
in Non-small Cell Lung Cancer
by: Xing ZHONG, et al.
Published: (2013-03-01) -
Epidermal growth factor receptor inhibitors in non-small cell lung cancer: current status and future perspectives
by: Mauro Zükin
Published: (2012-04-01) -
Advanced Research on Non-small Cell Lung Cancer with De Novo T790M Mutation
by: Xin WANG, et al.
Published: (2019-05-01)